Can China's brain tech make Elon's Neuralink open-skull surgery out of date?
A team led by China's Nankai University has completed what it calls the world's first human trial of a brain-computer interface (BCI) implanted via blood vessels, helping a paralysed patient regain limb movement.
Advertisement
Unlike the open-skull approach of Elon Musk's US-based neurotechnology company Neuralink, the Nankai University method reportedly reduces risk and shortens recovery time.
This research was led by Professor Duan Feng, vice dean of the university's medical college, and the interventional surgery was performed at the Fujian Sanbo Funeng Brain Hospital, according to a university statement.
A 67-year-old male patient with left hemiplegia from a cerebral infarction six months earlier, who was showing slow rehabilitation progress, underwent BCI interventional implantation.
Hemiplegia is a paralysis affecting one side of the body.
Advertisement
Under high-precision digital subtraction angiography (DSA) imaging guidance, surgeons inserted a stent electrode into the patient's intracranial vasculature, a network of blood vessels in the skull that supply blood to the brain, via a minimally invasive neck vein procedure, according to a university statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
3 hours ago
- South China Morning Post
China's rapid adoption of AI demands greater scrutiny of the social impact
The first half of 2025 has witnessed a wave of artificial intelligence (AI) adoption in China. The speed and extent of this trend has exceeded previous technology waves, such as the internet in the late 20th century or electricity before that. Thanks to the country's computing infrastructure and fundamental models from developers like DeepSeek, Alibaba Group Holding, Tencent Holdings, ByteDance and Baidu, China is probably among the world's most aggressive nations in adopting AI. The new technology is easily available at a reasonable cost – for individuals it is usually free – and an army of agents is ready to help deploy AI for businesses. Alibaba owns the South China Morning Post. China is eager to roll out AI partly because the country is engaged in fierce competition with the US, and the priority is clearly on achieving the growth and adoption of AI. China's tech giants and start-ups must relentlessly improve their AI technologies and promote their use to businesses and individuals, or they risk becoming irrelevant if they fall behind even for a few months. Visitors attend the World Artificial Intelligence Conference in Shanghai, July 6, 2023. Photo: Reuters Chinese businesses are also rushing to deepen the use of AI algorithms in their services to cut operation costs and improve efficiency. They are doing so with urgency over fears that a delayed application of AI would put them in a disadvantaged position in the market. For many Chinese users, AI tools are already part of their day-to-day life and work. In contrast to the perception that Beijing has placed a lot of 'guardrails' on AI, China's AI regulation so far has been limited. There are certain 'red lines'. For instance, Chinese chatbots are not allowed to generate answers that violate the country's strict online content rules, which has seen the rise of the popular game of feeding 'sensitive questions' to the chatbots and mocking their refusal to answer. Separately, China has maintained a registration system for fundamental AI models, which creates a hurdle for foreign AI companies wanting to enter the market. But the general development and adoption of AI is done in a freewheeling fashion. In fact, China does not have a centralised agency to oversee AI in general. The Cyberspace Administration of China is in charge of 'registration' of AI models; the Ministry of Industry and Information Technology is in charge of computing and cloud; and the National Development and Reform Commission oversees the use of data through its National Data Bureau'. The security and ethics of AI involve even more government departments. The DeepSeek logo is shown on a computer screen in this arranged photograph. Photo: dpa
South China Morning Post
3 hours ago
- South China Morning Post
New drug approval system takes Hong Kong closer to biomedical hub goal
Hong Kong has good reason to aspire to its own internationally recognised regime for approving pharmaceutical drugs . Intense global demand for Covid-19 vaccines remains fresh in the memory. The city also happens to rank No 2, behind only New York, as a market for biomedical and pharmaceutical companies to raise capital. To realise this goal, developing independent clinical trial capacity and a regulatory framework comparable with the US Food and Drug Administration would go a long way. It would also raise Hong Kong's standing as a medical innovation hub. Advertisement It is therefore good to hear from health authorities that the city will begin reviewing and approving drugs independently in phases from 2026. A new regulatory system is set to begin operating by the end of next year, with more new medications expected to hit the local market before long. To clear the way, the Department of Health has unveiled a plan to set up a centre for the regulation of medical products, with the aim of becoming a recognised international drug regulation authority. This is the final link in a road map for the development of primary drug evaluation, an approach foreshadowed in Chief Executive John Lee Ka-chiu's 2023 policy address. This will speed up product reviews. Primary evaluation means approving drugs based on their clinical trial data, without relying on registration approval from other regulatory authorities. A preparatory office for the centre was set up in June last year to study and plan for a drug regulatory regime. The department said primary evaluation was expected to be implemented gradually over five years. To that end, Hong Kong recently opened its first clinical trial institute , located in a cross-border tech zone. The development of Hong Kong as a biomedical hub not only means business opportunities for the city, but resonates with vast market potential on the mainland, where people cannot always afford new drugs approved in the US. As a rapidly ageing society, Hong Kong has a multipronged interest in recognition as an Asian pharmaceutical and biomedical hub with big potential for healthcare shaped by biotech and bioscience. Advertisement
South China Morning Post
12 hours ago
- South China Morning Post
Hong Kong aims to become referee in sports disputes with new scheme
Hong Kong authorities are seeking proposals from interested parties to run a two-year pilot programme for sports dispute resolution, a move experts have said is a key step in establishing a neutral third-party intervention mechanism for the growing sector. Observers said on Monday that such a programme would enhance the city's reputation as a leading legal and dispute mediation and arbitration hub, providing a specialised avenue for increasingly complex commercial disagreements within the global sports industry. The Department of Justice said it had prepared the invitation for proposals to identify a suitable administering body and a technology provider for the pilot scheme, with these two parties needing to submit a joint proposal by July 31. 'The appointed dispute resolution institution will administer the pilot scheme and provide institutional support for the conduct of mediation and arbitration,' a department spokesman said. 'To promote wider use of lawtech and online dispute resolution, the administering body shall partner with an online dispute resolution institution as a technology provider to provide the technological infrastructure and support required for the operation of the pilot scheme.' Lawtech, or law technology, refers to the use of technology to improve or replace traditional legal processes and services.
